Page 45 - NobleCon20-Book-Project

BioHarvest Sciences Inc.

SELECTED FINANCIAL ITEMS CNSX:BHSC

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue 3.24 4.52 5.34 6.03 19.13
Gross Profit 1.44 2.29 3.00 3.10 9.84
Gross Margin 45% 51% 56% 51% 51%
EBIT (2.01) (2.55) (1.42) (1.78) (7.76)
EBIT Margin -62% -56% -27% -29% -41%
Net Income to Common Shareholders (1.73) (7.24) (6.58) (0.69) (16.23)
Net Margin -53% -160% -123% -11% -85%

Balance Sheet Key Items
Total Assets 10.59 15.00 12.91 27.01 27.01
Cash & Short Term Investments 1.56 5.36 3.44 5.17 5.17
% of Assets 15% 36% 27% 19% 19%
Current Assets -Total 4.72 9.05 7.56 9.26 9.26
% of Assets 45% 60% 59% 34% 34%
Total Liabilities 18.34 29.86 16.10 20.31 20.31
% of Assets 173% 199% 125% 75% 75%
Current Liabilities - Total 14.60 26.47 13.32 8.94 8.94
% of Assets 138% 176% 103% 33% 33%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (7.75) (14.85) (3.18) 6.70 6.70
% of Assets -73% -99% -25% 25% 25%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.00) (2.99) (1.58) (0.96) (6.53)
Net Cash Flow - Investing (0.44) (0.29) (0.22) (1.93) (2.89)
Net Cash Flow - Financing 1.18 7.01 (0.12) 4.61 12.68

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference